Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.31 USD | -3.53% | +1.07% | -43.48% |
06-11 | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
06-11 | Sector Update: Health Care | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.48% | 786M | C- | ||
+23.13% | 46.93B | B- | ||
+37.21% | 39.08B | A | ||
-8.73% | 38.48B | B | ||
+28.09% | 31.01B | B | ||
-12.26% | 26.14B | C | ||
+10.57% | 25.88B | B- | ||
+32.23% | 12.53B | C+ | ||
-6.56% | 11.36B | B+ | ||
-12.56% | 10.65B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRDN Stock
- Ratings Viridian Therapeutics, Inc.